ReviewFrontiers in pharmacology2025
Metabolites of Astragalus membranaceus and their pro-apoptotic and cytotoxic activities: insights into targeted metabolic pathways.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Phytochemical Profiling, In Vitro Bioactivity, and Network Pharmacology ofMolecules (Basel, Switzerland) · 2026Article
- Review
- Astragaloside IV targets TUBB4B to inhibit proliferation and promote apoptosis of pituitary tumor cells via the STMN1/ERK pathway.International journal of molecular medicine · 2026Article
- Natural Products in Endometrial Cancer: Molecular Mechanisms, Preclinical Evidence, and Clinical Perspectives.Current issues in molecular biology · 2026Review
- Effects of Adding Astragali Radix and Inulae Radix on Fermentation Quality, Nutrient Preservation, and Microbial Community in Barley Silage.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astragalus membranaceus (Astragalus), a traditional Chinese herbal medicine, is well known for its immunomodulatory effects. Recent studies have demonstrated that Astragalus exhibits antiviral, anti-inflammatory, anti-aging, anti-atherosclerotic, antioxidant, and immune-enhancing activities, as well as pro-apoptotic and cytotoxic effects on tumor cells. It is increasingly used as an adjuvant therapy in oncology. The mechanisms underlying its pro-apoptotic and cytotoxic activities include inhibition of tumor cell proliferation and migration, modulation of tumor-associated metabolic pathways, induction of tumor cell apoptosis, cell cycle arrest, regulation of autophagy, targeting of the tumor microenvironment, inhibition of neo-angiogenesis, and enhancement of host immunity. This review provides a comprehensive summary of the active metabolites of Astragalus and their pro-apoptotic and cytotoxic mechanisms, with a focus on metabolic regulation, offering a theoretical basis for its rational application in tumor therapy. Future research aimed at precise metabolite-guided interventions could improve patient outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.